Injectable Hyaluronic Acid Hydrogel Containing Platelet Derivatives for Synovial Fluid Viscosupplementation and Growth Factors Delivery
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F23%3A10459038" target="_blank" >RIV/00216208:11110/23:10459038 - isvavai.cz</a>
Výsledek na webu
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=XUEQOOW6qu" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=XUEQOOW6qu</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1002/mabi.202200516" target="_blank" >10.1002/mabi.202200516</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Injectable Hyaluronic Acid Hydrogel Containing Platelet Derivatives for Synovial Fluid Viscosupplementation and Growth Factors Delivery
Popis výsledku v původním jazyce
Osteoarthritisis a highly prevalent musculoskeletal disorder characterized by degradation ofcartilage and synovial fluid (SF). Platelet derivatives as platelet-rich plasma (PRP) and platelet lysatehave great potential in the treatment of osteoarthritis because they contain biologicallyactive substances including growth factors (GFs). Rapid release of GFs andtheir short biological half-life are factors that can limit the therapeuticimpact of PRP therapy. Here, the first work that describes hydrogels based onpolyaldehyde derivative of hyaluronic acid (HA-OX) as carriers of plateletderivatives for in situ applications is presented, which can be a possiblesolution to the problem. HA-OX hydrogels containing 50% (w/w) of PRP or platelet lysate can be injected using a syringe due to low viscosity(<10 Pa s) and injection force (<20 N), and reach elastic modulus upto 2000 Pa. Insulin-like GF-1 and Platelet-derived GF-AB release from HA-OX hydrogels (mesh size 297-406 nm) by Fickian and non-Fickian diffusion respectively. The released PRP GFs maintain their ability to induce cell proliferation (87%-92%). Based on the obtained results, the unique concept of a new material that canrestore viscoelastic properties of SF and at the same time gradually deliver GFs from platelet derivatives is designed.
Název v anglickém jazyce
Injectable Hyaluronic Acid Hydrogel Containing Platelet Derivatives for Synovial Fluid Viscosupplementation and Growth Factors Delivery
Popis výsledku anglicky
Osteoarthritisis a highly prevalent musculoskeletal disorder characterized by degradation ofcartilage and synovial fluid (SF). Platelet derivatives as platelet-rich plasma (PRP) and platelet lysatehave great potential in the treatment of osteoarthritis because they contain biologicallyactive substances including growth factors (GFs). Rapid release of GFs andtheir short biological half-life are factors that can limit the therapeuticimpact of PRP therapy. Here, the first work that describes hydrogels based onpolyaldehyde derivative of hyaluronic acid (HA-OX) as carriers of plateletderivatives for in situ applications is presented, which can be a possiblesolution to the problem. HA-OX hydrogels containing 50% (w/w) of PRP or platelet lysate can be injected using a syringe due to low viscosity(<10 Pa s) and injection force (<20 N), and reach elastic modulus upto 2000 Pa. Insulin-like GF-1 and Platelet-derived GF-AB release from HA-OX hydrogels (mesh size 297-406 nm) by Fickian and non-Fickian diffusion respectively. The released PRP GFs maintain their ability to induce cell proliferation (87%-92%). Based on the obtained results, the unique concept of a new material that canrestore viscoelastic properties of SF and at the same time gradually deliver GFs from platelet derivatives is designed.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30100 - Basic medicine
Návaznosti výsledku
Projekt
—
Návaznosti
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Ostatní
Rok uplatnění
2023
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Macromolecular Bioscience
ISSN
1616-5187
e-ISSN
1616-5195
Svazek periodika
23
Číslo periodika v rámci svazku
4
Stát vydavatele periodika
DE - Spolková republika Německo
Počet stran výsledku
14
Strana od-do
2200516
Kód UT WoS článku
000930163600001
EID výsledku v databázi Scopus
2-s2.0-85147939224